Literature DB >> 18759624

The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures.

Kristopher T Kahle1, Kevin J Staley.   

Abstract

Seizures that occur during the neonatal period do so with a greater frequency than at any other age, have profound consequences for cognitive and motor development, and are difficult to treat with the existing series of antiepileptic drugs. During development, gamma-aminobutyric acid (GABA)ergic neurotransmission undergoes a switch from excitatory to inhibitory due to a reversal of neuronal chloride (Cl()) gradients. The intracellular level of chloride ([Cl()](i)) in immature neonatal neurons, compared with mature adult neurons, is about 20-40 mM higher due to robust activity of the chloride-importing Na-K-2Cl cotransporter NKCC1, such that the binding of GABA to ligand-gated GABA(A) receptor-associated Cl() channels triggers Cl() efflux and depolarizing excitation. In adults, NKCC1 expression decreases and the expression of the genetically related chloride-extruding K-Cl cotransporter KCC2 increases, lowering [Cl()](i) to a level such that activation of GABA(A) receptors triggers Cl() influx and inhibitory hyperpolarization. The excitatory action of GABA in neonates, while playing an important role in neuronal development and synaptogenesis, accounts for the decreased seizure threshold, increased seizure propensity, and poor efficacy of GABAergic anticonvulsants in this age group. Bumetanide, a furosemide-related diuretic already used to treat volume overload in neonates, is a specific inhibitor of NKCC1 at low doses, can switch the GABA equilibrium potential of immature neurons from depolarizing to hyperpolarizing, and has recently been shown to inhibit epileptic activity in vitro and in vivo in animal models of neonatal seizures. The fundamental role of NKCC1 in establishing excitatory GABAergic neurotransmission in the neonate makes it a tempting target of a novel mechanism-based anticonvulsant strategy that could utilize the well-known pharmacology of bumetanide to help treat neonatal seizures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759624     DOI: 10.3171/FOC/2008/25/9/E22

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  32 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 2.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

Review 3.  Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4.

Authors:  J Marc Simard; Kristopher T Kahle; Volodymyr Gerzanich
Journal:  J Neurosurg       Date:  2010-09       Impact factor: 5.115

4.  Enhanced GABAergic network and receptor function in pediatric cortical dysplasia Type IIB compared with Tuberous Sclerosis Complex.

Authors:  Carlos Cepeda; Véronique M André; Jason S Hauptman; Irene Yamazaki; My N Huynh; Julia W Chang; Jane Y Chen; Robin S Fisher; Harry V Vinters; Michael S Levine; Gary W Mathern
Journal:  Neurobiol Dis       Date:  2011-08-23       Impact factor: 5.996

5.  KCC2 function modulates in vitro ictogenesis.

Authors:  Shabnam Hamidi; Massimo Avoli
Journal:  Neurobiol Dis       Date:  2015-04-26       Impact factor: 5.996

6.  Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits.

Authors:  Doris D Wang; Arnold R Kriegstein
Journal:  Cereb Cortex       Date:  2010-07-12       Impact factor: 5.357

Review 7.  Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

8.  Biochemical properties of the sensitivity to GABAAergic ligands, Cl-/HCO3--ATPase isolated from fish (Cyprinus carpio) olfactory mucosa and brain.

Authors:  Sergey Menzikov
Journal:  Fish Physiol Biochem       Date:  2017-12-07       Impact factor: 2.794

Review 9.  Clinical management of seizures in newborns : diagnosis and treatment.

Authors:  Linda G M van Rooij; Marcel P H van den Broek; Carin M A Rademaker; Linda S de Vries
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 10.  Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies.

Authors:  H Steve White; Wolfgang Löscher
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.